Projects
Humanized Immune Liver Mouse and 3D in vitro models for the study and therapy of liver disease (HILIM-3D) Ghent University
One will develop robust methods to differentiate into cells with PSC more characteristics of primary hepatocytes, HepSC, HSC and liver-specific immune cells, including the ability to transplant these cells into the respective compartments in vivo.
Quest for tissue biomarkers for immune therapy in non-small cell lung cancer KU Leuven
The research and quest for tissue biomarkers for immune therapy in non-small cell lung cancer. Defining immunological heterogeneity within tumours and correlate intra-tumour heterogeneity with response on immune treatment
SRP (Groeiers): Next-generation gene therapy by computational vector design and immune stealth nanotechnology Vrije Universiteit Brussel
Humanized Immune Liver Mouse and 3D in vitro models for the study and therapy of liver disease. KU Leuven
The goal is the development of high quality in vitro 3D cell culture systems and in vivo humanized mouse models for studying hepatotropic virus infections, evaluation of efficacy, metabolism and toxicity of medication, and study of hepatocellular fibrosis.
Development of novel "immune stealth" nanotechnology for gene therapy of hemophilia: pre-clinical validation and underlying mechanisms Vrije Universiteit Brussel
Investigation of immune and oxidative stress aberrancies in ADHD and the potential of polyphenol-rich plant extract supplementation in ADHD therapy. University of Antwerp
Investigation of immune and oxidative stress aberrancies in ADHD and the potential of polyphenol-rich plant extract supplementation in ADHD therapy. University of Antwerp
Investigation of immune and oxidative stress aberrancies in ADHD and the potential of polyphenol-rich plant extract supplementation in ADHD therapy. University of Antwerp
Overcoming melanoma resistance to targeted therapy and immune checkpoint inhibitors KU Leuven
With 5-year survival rates for patients with metastatic disease around 30%, cutaneous melanoma is the leading cause of skin cancer related deaths. Standard of care for melanoma envisage a combination of BRAF and MEK inhibitors, a viable option only for melanoma patients carrying BRAF mutations, or immunotherapy. Both strategies are very efficient, however not all the patients respond to the treatment and often the responses are only ...